Plasma Fraction Market Growth, Trends, and Key Players
The global plasma fraction market was valued at USD 32.75 billion in 2023 and is expected to reach USD 72.86 billion by 2034, growing at a compound annual growth rate (CAGR) of 7.54% from 2024 to 2034. This growth is driven by the increasing demand for plasma-derived medicines used to treat conditions such as rabies, tetanus, shock, and trauma, further boosting the expansion of the plasma fraction industry.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5304
Market Overview
Plasma fractionation separates protein components from human blood plasma for pharmaceutical research and therapeutic uses. The rise in global diseases like immunodeficiencies and genetic disorders is driving demand for high-quality medicines, boosting the plasma fraction market. Plasma is composed of 91.5% water, 7% protein (mainly Albumin, Immunoglobulin, and Fibrinogen), and 1.5% salt.
Plasma Fraction Market Trends
In May 2024, Aegros, a biotech startup, raised $20 million to expand immunoglobulin production. In June 2024, Takeda invested $230 million to increase plasma-derived therapy production in Los Angeles.
Leading Companies in the Plasma Fraction Market
Several companies are at the forefront of the plasma fraction market, contributing to the development and production of plasma-derived therapies:
- Baxter International: A global healthcare leader, Baxter focuses on innovations in plasma-based therapies, offering treatments for immunodeficiencies and other complex diseases.
- Bayer: Known for its expertise in pharmaceuticals, Bayer plays a key role in the production of plasma-derived medicines, advancing treatment options in critical care.
- Biotest: Specializing in immunology and hematology, Biotest manufactures plasma proteins that are used in a wide range of therapeutic applications.
- BPL (Bio Products Laboratory): A key player in the market, BPL is dedicated to producing life-saving plasma therapies, especially in the areas of immunology and hematology.
- CBPO (China Biologic Products): As one of China’s largest producers of plasma-derived products, CBPO focuses on high-quality therapies for chronic diseases and immunodeficiencies.
- CSL Behring: A leader in plasma protein therapeutics, CSL Behring is known for its broad portfolio of life-saving treatments for rare and serious conditions.
- Fusion Healthcare: A newer player in the field, Fusion Healthcare works on sustainable plasma-derived products with a focus on immunoglobulin therapies.
- Grifols: A global biopharmaceutical company, Grifols is a major producer of plasma-derived therapies, including treatments for bleeding disorders and immune deficiencies.
- Kedrion Biopharma Inc.: Specializing in human plasma-derived therapies, Kedrion plays a critical role in treating patients with rare diseases and immune disorders.
- KM Biologics: KM Biologics is known for producing vaccines and plasma-derived products, helping to address both infectious diseases and immunological conditions.
- LBF USA: A part of the LFB Group, LBF USA focuses on developing and delivering high-quality plasma-based treatments for patients worldwide.
- LFB Group: Based in France, LFB is a leading producer of plasma-derived medicines, with a focus on immunology, hematology, and intensive care treatments.
- Nanyue Bio: A Chinese company, Nanyue Bio specializes in plasma protein products used for treating various blood disorders and immune system conditions.
- Octopharma: A Swiss company, Octopharma produces a broad range of plasma-derived therapies, focusing on hematology, immunology, and critical care.
- RAAS: A prominent player in the plasma fraction market, RAAS produces therapies that are vital for treating rare diseases and chronic conditions.
- Takeda Pharmaceuticals: With a strong presence in plasma-derived therapies, Takeda is a global leader in producing treatments for immune diseases and bleeding disorders.
- Tiantan Bio: Based in China, Tiantan Bio focuses on producing plasma-derived products for various therapeutic areas, including immunology and hematology.
- Weiguang Bio: A key company in the Chinese market, Weiguang Bio develops plasma-derived treatments for a range of medical conditions, helping improve patient outcomes worldwide.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/plasma-fraction-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5304
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
